Gastric cancer drug cadonilimab under Long-Term observation
NCT ID NCT07547787
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is not testing a new treatment. Instead, it follows up with 610 people who previously received cadonilimab for advanced gastric cancer in earlier trials. Researchers will collect long-term survival data to see if the drug's benefits last. No additional medication is given during this observational phase.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could provide evidence that cadonilimab offers lasting survival benefits for people with advanced gastric cancer.
- What could go wrong
- This is an observational follow-up, not a new treatment trial. It cannot prove effectiveness on its own, and results may be limited by the original study's design.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, China